Ubiquigent, a drug discovery firm specialising in ubiquitin cell-signalling, has received £500k ($800k) investment from commercialisation firm the IP Group and government agency Scottish Enterprise (SE), via SE’s investment arm the Scottish Investment Bank. The firm, which is a spin-out of the University of Dundee and still located on campus, will use the latest round…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
